Ignite Creation Date:
2024-05-05 @ 9:45 PM
Last Modification Date:
2024-10-26 @ 10:09 AM
Study NCT ID:
NCT00956085
Status:
COMPLETED
Last Update Posted:
2017-06-21
First Post:
2009-08-10
Brief Title:
Memantine Augmentation in Treatment-Resistant Adults With Obsessive-Compulsive Disorder
Sponsor:
New York State Psychiatric Institute
Organization:
New York State Psychiatric Institute
Study Overview
Official Title:
Open -Label Trial on the Effects of Memantine in Adults With Obsessive-Compulsive Disorder After a Single Ketamine Infusion
Status:
COMPLETED
Status Verified Date:
2017-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Obsessive-compulsive disorder OCD is a common psychiatric illness that affects up to 2-3 of the population People with OCD experience anxiety-provoking intrusive thoughts known as obsessions and feel compelled to perform repetitive behaviors or compulsions The only medications proven effective for OCD are serotonin reuptake inhibitors SRIs but even with SRI treatment most patients continue to experience significant OCD symptoms impaired functioning and diminished quality of life Recent evidence suggest that a different neurotransmitter glutamate may contribute to the symptoms in OCD Medications that target glutamate hold promise for ameliorating symptoms for those patients continuing to suffer from OCD In this study the investigators are recruiting patients to receive the drug memantine which is thought to modulate the neurotransmitter glutamate added to whatever other OCD medications they are taking
Open label memantine will be titrated in 5mg increments weekly to target dose of 10mg po bid for up to 6 weeks Memantine will be continued to 12 weeks in those with treatment response13 either previous response to ketamine 35 Y-BOCS reduction 1 week after IV ketamine or current response to memantine 35 Y-BOCS reduction from pre- to post-6 weeks of memantine
Open label memantine will be titrated in 5mg increments weekly to target dose of 10mg po bid for up to 6 weeks Memantine will be continued to 12 weeks in those with treatment response13 either previous response to ketamine 35 Y-BOCS reduction 1 week after IV ketamine or current response to memantine 35 Y-BOCS reduction from pre- to post-6 weeks of memantine
Detailed Description:
see above
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None